Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIMID filgotinib study in refractory Behçet's disease or idiopathic inflammatory myopathies
NL-OMON59338Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of filgotinib in Behçet's disease (BD) and Autoimmune Myopathies (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: EuroQol 5D-5L, Behçet's Disease Current Activity Form and 1 more. Started May 2024; status: recruiting.
02
Drugs
filgotinib
03
Conditions
Behçet's disease (BD)Autoimmune Myopathies
Beyond the preview
Go deeper on NL-OMON59338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59338.